Jazz Pharmaceuticals (JAZZ) Gross Margin
Jazz Pharmaceuticals (JAZZ) currently has a gross margin of 0.0%. Margins are stable over recent quarters. The company is a Biotech cannabis company trading on the NASDAQ.
Current Gross Margin
0.0%
Margin Trend
Stable
Latest Quarter Margin
0.0%
Quarterly Gross Margin
| Period | Revenue | COGS | Gross Profit | Gross Margin |
|---|---|---|---|---|
| FY2025 Q3 | $1.13B | $0 | $0 | 0.0% |
| FY2025 Q2 | $1.05B | $0 | $0 | 0.0% |
| FY2025 Q1 | $897.8M | $0 | $0 | 0.0% |
| FY2024 Q4 | $1.09B | $0 | $0 | 0.0% |
| FY2024 Q3 | $1.05B | $0 | $0 | 0.0% |
| FY2024 Q2 | $1.02B | $0 | $0 | 0.0% |
| FY2024 Q1 | $902.0M | $0 | $0 | 0.0% |
| FY2023 Q4 | $1.01B | $0 | $0 | 0.0% |
Frequently Asked Questions
What is JAZZ's current gross margin?+
Gross margin for Jazz Pharmaceuticals is calculated as (revenue minus cost of revenue) divided by revenue, expressed as a percentage. It measures how efficiently the company converts sales into gross profit before operating expenses. Higher margins indicate better pricing power or lower production costs.
What is a good gross margin for cannabis companies?+
Cannabis gross margins vary widely by sub-sector. Retailers typically see 40-55%, vertically integrated MSOs 45-60%, and LPs 20-45%. Jazz Pharmaceuticals's margin should be compared to peers in the same sub-sector for meaningful context. Margins above 50% generally indicate strong pricing power.
Why do JAZZ's margins change quarter to quarter?+
Gross margin fluctuations for Jazz Pharmaceuticals can result from changes in product mix, pricing pressure from competition, input cost changes (e.g., energy, labor), inventory write-downs, or scaling into new markets where initial costs are higher. Seasonal harvest patterns can also affect margins for cultivators.